BILLS-107hr717ih.pdf

2001 each year January 8 1 later than January 1, 2003 8 years FEBRUARY 14, 2001 biennially the fiscal years 2001 through 2005 2 years 1987 5 years later than 1 year a fiscal year 20 years of age

SESSION H. the ‘‘Muscular Dystrophy Co- 21

States the Trust Territory the Virgin Islands Oklahoma Michigan Kentucky Minnesota Guam Florida Duchenne the United States of America Samoa North Carolina Virginia the District of Columbia Oregon

IH appro- 8 Pacific Islands

American

NIH SEC the National Institutes of Health Committee Health and Human Services CONGRESS State CENTERS OF EXCELLENCE Disease Control and Prevention the Centers for Disease Control and Prevention nating Committee Senate Health and Human Development the Muscular Dystrophy Coordinating CONGRESS.—The Coordinating the Public Health Service 441B. GENERAL.—The Committee Food and Drugs THE HOUSE OF REPRESENTATIVES TION OF ACTIVITIES OF NATIONAL TIAHRT INTER-AGENCY FLETCHER tional Institute of Arthritis Energy and Commerce the Centers for Disease Con- the Public Health Service Act DUCHENNE the Food and Drug the National Institute of Child ICAL Centers for Disease Control and Prevention Health the Commonwealth of Puerto Rico National Institutes volve the Committee on Health, Education Human Services Centers DMD House the National Institutes Administration ELIGIBILITY.—To House of Representa- the Department of 17 Education

Duchenne Duchenne muscular dystrophy Duchenne 1 DUCHENNE MUSCULAR GORDON BRYANT MYRICK TURNER KELLER RODRIGUEZ HOSTETTLER MURTHA CRAMER WICKER Duchenne 24 BROWN BLUMENAUER Duchenne 6 BENTSEN GREENWOOD GUTKNECHT SKELTON KING HASTINGS MANZULLO EHLERS MCHUGH MCCRERY GILLMOR GOODE EMERSON LEACH GRANGER WOLF ROHRABACHER LATOURETTE HUNTER CALVERT QUINN UPTON PICKERING BACHUS GANSKE WALDEN KINGSTON Duchenne 4 WALSH WELLER GILMAN

duchenne muscular dystrophy muscular dystrophy director nih nih symptoms institutes muscle gene general director director childhood chance research